Ubi Titer Issue #5
Biologics AI Beyond Generation: Selectivity and Formulation
The hard problems in biologics AI aren't just generation anymore — they're ligase selectivity, dual-epitope targeting, and the formulation mechanics behind clinical durability.
- molecular glues
- E3 ligases
- GPCR antibodies
- dual-epitope antibodies
- ocular pharmacokinetics
What this issue covers
- 1.Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22
AbbVie shows that single-atom changes to a molecular glue degrader can reprogram which cellular disposal machinery it recruits — turning ligase choice into a tunable design parameter.
- 2.Fully Human Antagonistic Antibodies Targeting FPR2 Through Dual Extracellular-Loop Engagement for Gastric Cancer Therapy
A new antibody blocks a cancer-linked receptor by gripping two separate loops on its surface at once, offering an early proof-of-concept for a target that's historically been hard to drug with antibodies.
- 3.Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
A population PK analysis across 2,744 patients shows that a widely-used eye biologic's extended dosing interval comes from a genuine formulation effect on ocular clearance, not just from giving a bigger dose.
Paper 1 · Cell Chemical Biology
Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22
AbbVie shows that single-atom changes to a molecular glue degrader can reprogram which cellular disposal machinery it recruits — turning ligase choice into a tunable design parameter.
Core finding
A series of molecular glue degraders targeting SMARCA2/4 was characterized in detail, showing that the choice of which E3 ubiquitin ligase gets recruited to do the degrading is not fixed by the degrader's overall scaffold, but can be switched with minimal chemical changes.
What is novel
One compound in the series degrades its target exclusively through one ligase (DCAF16), while a one-carbon variant recruits a second ligase (FBXO22) as well, and yet another single substitution reverts to the first ligase alone. This is a clear demonstration that ligase selectivity in this class of molecule is programmable rather than inherent.
Limitations
The work is confined to one target family (SMARCA2/4) and doesn't establish how broadly this tunability generalizes to other molecular glue chemistries or targets.
Why it matters in context
Related work from an academic-industry collaboration has explored dual E3 ligase recruitment for the same target family around the same period, suggesting the field is converging on tunable ligase selectivity as a genuine new design axis for targeted protein degradation, rather than a one-off observation.
Paper 2 · Antibody Therapeutics
Fully Human Antagonistic Antibodies Targeting FPR2 Through Dual Extracellular-Loop Engagement for Gastric Cancer Therapy
A new antibody blocks a cancer-linked receptor by gripping two separate loops on its surface at once, offering an early proof-of-concept for a target that's historically been hard to drug with antibodies.
Core finding
Fully human antibodies were developed against FPR2, a receptor that H. pylori exploits to help drive gastric cancer progression, using a design that engages two separate extracellular loops of the receptor simultaneously rather than just one.
What is novel
Most antibody efforts against this class of receptor latch onto a single exposed loop or the very tip of the protein, since G-protein-coupled receptors bury most of their surface in the cell membrane. Engaging two loops at once is a structurally more demanding approach that, per the authors' modeling, physically covers the receptor's active site.
Limitations
All results are from cell-based assays; there is no in vivo efficacy data yet, and the paper does not report a binding affinity value for the lead antibody, making it hard to judge how it would compare to more mature candidates.
Why it matters in context
This sits within a broader push to make antibodies work against G-protein-coupled receptor targets, a receptor class long considered difficult for antibody therapeutics and more commonly addressed with small molecules — dual-epitope engagement is one of several strategies researchers are testing to make antibody approaches viable here.
Paper 3 · CPT: Pharmacometrics & Systems Pharmacology
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
A population PK analysis across 2,744 patients shows that a widely-used eye biologic's extended dosing interval comes from a genuine formulation effect on ocular clearance, not just from giving a bigger dose.
Core finding
An integrated pharmacokinetic model built from 2,744 participants across 16 clinical trials isolated ocular clearance as the parameter driving how long a therapeutic antibody-like fusion protein stays active in the eye, showing it is roughly 39% slower for a newer, higher-dose formulation of aflibercept than for the original version.
What is novel
The slower ocular clearance is tied specifically to the change in drug product formulation, not merely to giving a larger dose — the analysis directly tested a simple dose-response explanation against a formulation-specific effect and found the formulation explanation fit the data meaningfully better.
Limitations
The paper identifies and precisely quantifies the clearance difference but does not explain the underlying formulation chemistry responsible for it; that mechanistic question is left open for future work.
Why it matters in context
This provides the mechanistic backbone for why a next-generation formulation of a major eye biologic can be dosed less frequently than its predecessor while maintaining efficacy, a competitive dimension across the anti-VEGF eye disease treatment landscape where reducing injection frequency is a major differentiator between drugs.
Primary papers
- [1] Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22 (Cell Chemical Biology)
- [2] Fully Human Antagonistic Antibodies Targeting FPR2 Through Dual Extracellular-Loop Engagement for Gastric Cancer Therapy (Antibody Therapeutics)
- [3] Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products (CPT: Pharmacometrics & Systems Pharmacology)